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Meteorin-like/Meteorin-β protects heart against
cardiac dysfunction
Celia Rupérez1,2, Gemma Ferrer-Curriu1,2, Aina Cervera-Barea1,2, Laura Florit1,2, Mariona Guitart-Mampel3,4, Gloria Garrabou3,4,
Mònica Zamora5, Fàtima Crispi5, Joaquim Fernandez-Solà6, Josep Lupón7, Antoni Bayes-Genis7, Francesc Villarroya1,2, and
Anna Planavila1,2
Meteorin-like/Meteorin-β (Metrnl/Metrnβ) is a secreted protein produced by skeletal muscle and adipose tissue that exerts
metabolic actions that improve glucose metabolism. The role of Metrnβ in cardiac disease is completely unknown. Here, we
show thatMetrnβ-null mice exhibit asymmetrical cardiac hypertrophy, fibrosis, and enhanced signs of cardiac dysfunction in
response to isoproterenol-induced cardiac hypertrophy and aging. Conversely, adeno-associated virus–mediated specific
overexpression of Metrnβ in the heart prevents the development of cardiac remodeling. Furthermore, Metrnβ inhibits cardiac
hypertrophy development in cardiomyocytes in vitro, indicating a direct effect on cardiac cells. Antibody-mediated blockage
of Metrnβ in cardiomyocyte cell cultures indicated an autocrine action of Metrnβ on the heart, in addition to an endocrine
action. Moreover, Metrnβ is highly produced in the heart, and analysis of circulating Metrnβ concentrations in a large cohort of
patients reveals that it is a new biomarker of heart failure with an independent prognostic value.
Introduction
Meteorin-β protein (Metrnβ), also known as Meteorin-like
(Metrnl) or IL-41 (Ushach et al., 2018; Bridgewood et al., 2019;
Rao et al., 2014), is a recently identified hormone that is pro-
duced by skeletal muscle and adipose tissue upon stimulation by
exercise and cold exposure, respectively. Rao et al. (2014) re-
ported that Metrnβ promotes energy expenditure and favors
glucose tolerance through the induction of alternatively acti-
vated macrophages at adipose depots and promotion of adipose
tissue browning. Further research in Metrnβ transgenic mice
revealed that peroxisome proliferator–activated receptor-γ
(PPARγ) contributes to the beneficial effects of Metrnβ in adi-
pose tissue (Li et al., 2015). In skeletal muscle, Metrnβ attenuates
inflammation and insulin resistance via AMP-activated protein
kinase and PPARδ-dependent pathways (Jung et al., 2018).
Metrnβ has been associated with innate immunity, acquired
immunity, and inflammatory pathways and is strongly induced
in alternatively activated macrophages (Ushach et al., 2018;
Ushach et al., 2015). Recent studies in humans have shown that
Metrnβ levels are decreased in obese and diabetic patients and
negatively correlate with glucose levels and insulin resistance
(Lee et al., 2018; Pellitero et al., 2018). Metrnβ levels have been
associated with the presence and severity of coronary artery
disease in humans (Liu et al., 2019). Finally, very recently, it has
been shown thatMetrnβ attenuates the cardiotoxicity associated
with chemotherapy in cancer treatments (Hu et al., 2020). To
date, however, the role of Metrnβ during cardiac disease has not
been explored.
The term “cardiokine” has emerged in recent years to name
proteins secreted from the heart that have autocrine, paracrine,
and/or endocrine functions crucial for the maintenance of car-
diac function and other systemic actions (Doroudgar and
Glembotski, 2011). Because of their extracellular localization,
cardiokines show promise as biomarkers, therapeutic targets, or
even therapeutic agents (Planavila et al., 2017).
Cardiac hypertrophy and subsequent progression to heart
failure (HF) represent a major cause of morbidity and mortality
in industrialized countries. The defining features of cardiac
hypertrophy are enhancedprotein synthesis, increased cardiomyocyte
.............................................................................................................................................................................
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size, a greater degree of sarcomere organization, and a shift in
the metabolic energy source from fatty acids to glucose (van
Bilsen et al., 1998). Inflammation also plays an important role
in hypertrophic responses in the heart (Smeets et al., 2008a;
Planavila et al., 2011). HF remains a critical health problem,
and the identification of underlying molecular targets and
novel protective agents is of crucial importance for improving
the efficacy of preventive and therapeutic strategies.
The observation of a very high expression of Metrnβ in the
heart prompted us to analyze the role of Metrnβ as a secreted
protein in cardiac tissue. We observed that mice lacking Metrnβ
are prone to develop cardiac alterations and that cardiac-specific
recovery of Metrnβ expression prevents hypertrophic induc-
tion. Moreover, the signals that promote hypertrophy also in-
duce cardiac Metrnβ expression and protein secretion in vivo
and in vitro. Finally, the circulating levels of Metrnβ are in-
creased in HF patients, and Metrnβ appears as a new biomarker
for cardiac prognosis in these patients.
Results
Metrnβ is expressed in heart, produced and secreted by
cardiomyocytes, and up-regulated upon cardiac stress in mice
and humans
We analyzed the relative expression levels of the Metrnβ tran-
script in various mouse tissues.We found the highest expression
level in the heart, where the Metrnβ mRNA level was higher
than that found in the other tissues tested, including tissues
previously considered to be sources of Metrnβ, such as adipose
tissue and skeletal muscle (Fig. 1 a). In human tissue samples, the
expression levels of Metrnβ transcript in the heart were lower
than in adipose tissue but twice those in liver and skeletal
muscle (Fig. S1 a).
Induction of cardiac hypertrophy in distinct experimental
models in mice based on treatment with the hypertrophic agent
isoproterenol (ISO), transversal aortic constriction (TAC), and
angiotensin II (AngII)–induced hypertension significantly in-
creased the expression levels of Metrnβ inmouse heart (Fig. 1 b).
Metrnβ circulating levels are significantly induced after ISO-
induced cardiac hypertrophy (Fig. 1 c).
Furthermore, Metrnβ transcript expression levels were sig-
nificantly induced in hearts from human patients suffering from
HF (Fig. 1 d). Immunohistochemical analysis revealed a signifi-
cant increase in theMetrnβ protein levels in patients affected by
distinct types of cardiomyopathy (hypertensive, valvular, and
idiopathic; Fig. 1 e).
Isolation of cardiac cells from rat heart indicated that Metrnβ
is preferentially expressed in cardiomyocytes rather than in
cardiac fibroblasts (CFs; Fig. 1 f). Our analysis of Metrnβ ex-
pression in primary cultures of neonatal cardiomyocytes
(NCMs) showed that Metrnβ mRNA levels were significantly
increased following exposure to the hypertrophic agent phen-
ylephrine (PE; Fig. 1 g). Finally, to determine whether Metrnβ
was actually secreted by cardiomyocytes, we analyzed Metrnβ
protein levels in NCM culture media. The basal rate of Metrnβ se-
cretion inmedia under control conditions was∼0.04 ngml−1 24 h−1.
After treatment with PE, the rate of Metrnβ protein secretion by
NCMs in culture was significantly increased, reaching∼0.08 ngml−1
24 h−1 (Fig. 1 g). These results indicate that the heart reacts to
hypertrophy induction and other cardiac insults by inducing
Metrnβ expression and that cardiomyocytes are active cells for
Metrnβ expression and release, especially in response to the in-
duction of cardiac cell hypertrophy.
PPARα controls Metrnβ expression in heart
Next, we analyzed the mechanisms that are responsible for
controlling Metrnβ expression and responsiveness in the heart
in the context of hypertrophy-inducing conditions. Previous
studies showed that the PPARα pathway protects the heart from
cardiac hypertrophy (Planavila et al., 2011; Smeets et al., 2008a;
Smeets et al., 2007; Smeets et al., 2008b), and members of the
PPAR family of transcription factors have been shown to regu-
late Metrnβ in adipose and skeletal muscle tissues (Jung et al.,
2018; Li et al., 2015). Accordingly, we first studied Metrnβ ex-
pression in hearts from Pparα-null mice under basal conditions
and after ISO treatment–based induction of cardiac hypertrophy
(Fig. 1 h). Cardiac Metrnβ expression was reduced in Pparα-null
mice under basal conditions. As expected, ISO treatment in-
duced an increase in the MetrnβmRNA expression levels of WT
mice. However, the induction of Metrnβ by ISO was completely
abrogated in Pparα-null mice.
The involvement of the PPARα pathway in controlling car-
diac Metrnβ expression was further confirmed in vitro in NCMs
(Fig. 1 i). Adenoviral vector (Ad)–mediated overexpression of
PPARα in NCMs led to a significant increase in both Metrnβ
transcript levels and the amount of Metrnβ protein secreted to
the culture media. In contrast, the PPARα inhibitor GW6471
significantly attenuated the increase in Metrnβ transcript levels
elicited by PE. Collectively, these results indicate that the PPARα
pathway critically controls Metrnβ expression in the heart.
Cardiac damage is enhanced in Metrnβ−/− mice
Given our observations that the heart is a relevant expression
site and source of Metrnβ, we next analyzed the role of Metrnβ
in the heart by determining the impact of Metrnβ ablation
(Metrnβ−/−) in mice. 2-mo-old Metrnβ−/− mice did not show any
marked alteration in general morphometric or metabolic pro-
files under basal conditions (Table S1). Only reductions in in-
guinal white adipose tissue depots and reduced triglycerides
were observed. No genotype-related difference in blood pres-
sure was found under any tested condition (Table S2). We an-
alyzed the hearts fromMetrnβ−/−mice at baseline and after 7 d of
exposure to continuous ISO infusion to experimentally induce
cardiac hypertrophy. Histological examination of H&E-stained
left ventricular posterior wall (LVPW) and septum tissue sec-
tions revealed that the cardiomyocyte cross-sectional area (CSA)
was larger in Metrnβ−/− mice than in WT mice at both sites
(Fig. 2, a and b). ISO treatment significantly increased CSA in
both Metrnβ−/− and WT mice, but the post-ISO increase in CSA
was much greater in the septum of Metrnβ−/− mice. ISO signif-
icantly increased the heart weight/tibia length (HW/TL) ratio
and the dimensions of interventricular septal (IVS), LVPW, and
left ventricular internal diameter (LVID) in systole, regardless of
genotype, in our two-way ANOVA analysis, indicating cardiac
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Figure 1. Metrnβ is expressed and released by cardiac cells, up-regulated in response to hypertrophic stimuli, and controlled by the PPARα pathway.
(a)Metrnβ expression levels in heart, brown adipose tissue (BAT), inguinal white adipose tissue (iWAT) and epididymal white adipose tissue (eWAT), liver, and
skeletal muscle of adult mice (n = 5 mice/group). (b)MetrnβmRNA levels in mouse heart after induction of cardiac hypertrophy by 7 d of ISO infusion, 1 mo of
TAC, or 7 d of AngII (n = 6 mice/group; Student’s t test; P values are 0.0143, 0.0374, 0.0003). (c) Circulating Metrnβ protein levels (n = 6 mice/group; Student’s
t test; P < 0.0001). (d) Cardiac Metrnβ expression levels in control individuals (CT; n = 5) and HF patients (n = 6); Mann-Whitney test; P = 0.0317. (e) Metrnβ
immunohistochemistry in human hearts and quantification of the Metrnβ expression index as the ratio of positively stained to negatively stained myocytes. CT
(n = 6), hypertension (HT; n = 11 non-cardiomyopathy [non-CMP] and n = 10 CMP), valvular (VAL; n = 5), idiopathic (ID; n = 3). Mann-Whitney test; P = 0.0402,
0.0152, 0.0238. Magnification, 20×. Scale bars, 25 µm (inset) and 50 µm. Red arrowheads show positive staining. (f) Metrnβ mRNA levels in the CM and CF
fractions from isolated rat hearts. Data are representative of four independent experiments; Student’s t test; P = 0.0004. (g)MetrnβmRNA levels in NCMs and
protein levels in culture media after PE stimulation for 24 h. Data are representative of four independent experiments; Student’s t test; P values are 0.0009,
0.0034. (h)MetrnβmRNA levels in WT littermates and PPARα−/− mice injected with ISO (i.p.) for 7 d (n = 5 mice/group; one-way ANOVA; P values are 0.0182,
0.0031). (i)MetrnβmRNA and protein levels in NCMs overexpressing PPARα (AdPPARα) or control vector (AdNull; 10 IFU/cell; data are representative of three
independent experiments; Student’s t test; P values are 0.0043, 0.001), and MetrnβmRNA levels in NCMs treated with PE and the PPARα antagonist GW6471
(1 µM), alone or in combination, for 24 h (data are representative of four independent experiments; one-way ANOVA; P values are 0.0494, #0.0077, *0.0448).
Results are expressed as mean ± SEM (*, P < 0.05 compared with control human hearts, WT control mice, or control cells; #, P < 0.05 compared with ISO-
treated WT animals [h] or PE-stimulated cells [i]).
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Figure 2. Metrnβ-null mice develop enhanced cardiac alterations in response to ISO infusion. 2-mo-old WT littermates (gray bars) and Metrnβ−/− (white
bars) mice were continuously infused with ISO for 7 d to experimentally induce heart hypertrophy. (a) Representative histological sections of hearts stained
with H&E were used to determine cardiomyocyte CSA. Magnification, 20×. Scale bar, 50 µm. (b) Quantification of cardiomyocyte CSA in the LVPW (P values
are 0.0011, <0.0001, 0.0368, <0.0001) and theseptum (S; P values are 0.0008, 0.0047, 0.0001, 0.013). (c) IVS and LVPW in systole (s) and diastole (d) assessed
by echocardiography. P values are 0.0111, 0.043, 0.0046, 0.0006, 0.0274, <0.0001, 0.0011, 0.0004, 0.0492. (d) mRNA expression of the hypertrophy marker
genes Nppa and Acta1 in the LVPW and the septum (S; P values are <0.0001, 0.0089, <0.0001, 0.0008). (e)mRNA expression of the fibrosis markers Col3a1 and
Tgfb in the LVPW and the septum (S; P values are <0.0001, <0.0001, 0.0018, <0.0001, 0.0122, 0.0031). (f) Determination of fibrosis in histological sections by
Rupérez et al. Journal of Experimental Medicine 4 of 18
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hypertrophy development (Fig. 2 c and Table 1). However,
Metrnβ−/− mice exhibited exacerbated induction of cardiac IVS
after diastole (IVSd) and IVS dimensions in response to ISO,
whereas they also showed a lesser increase in LVPWd and LVPW
dimensions.
Thus, it was concluded that the absence of Metrnβ caused an
abnormal cardiac remodeling, causing a much greater increase
in the thickness and area of the cardiomyocytes, especially in the
IVS in response to ISO-induced hypertrophic challenge.
The morphological signs of heart alterations in Metrnβ−/−
mice were accompanied by functional disturbances (Table 1).
Left ventricular ejection fraction (LVEF) and fractional short-
ening (FS) were significantly increased by ISO treatment in
Metrnβ−/− mice. Doppler measurements showed a significant
increase in the aortic peak velocity, a measure of cardiac con-
tractility, and aortic diameter in response to ISO treatment in
both genotypes, although the values were greater in Metrnβ−/−
mice. The parameters of diastolic function E peak and mitral
deceleration were altered in Metrnβ−/− mice: E peak tended to
increase in Metrnβ−/− mice after ISO treatment (P = 0.06), and
mitral deceleration was significantly reduced in mice lacking
Metrnβ, indicating reduced relaxation times during diastole.
Collectively, these data indicate that the asymmetrical hyper-
trophy developed in Metrnβ−/− mice is associated with a higher
degree of contractility necessary to compensate the thickening
of the septal wall, a phenotype resembling patients with hy-
pertrophic cardiomyopathy (Marian and Braunwald, 2017;
Yousefzai et al., 2017).
The mRNA expression levels of the hypertrophy marker
genes encoding atrial natriuretic factor (Nppa) and α-actinin
(Acta1) were similar in WT and Metrnβ−/− mice under basal
conditions (Fig. 2 d). In the LVPW, ISO infusion caused similar
increases in Nppa in both genotypes but triggered a significant
induction of Acta1 only in Metrnβ−/− mice. In the septum, ISO
infusion caused no increase in Nppa in both genotypes, but it
also triggered a significant induction of Acta1 only in Metrnβ−/−
mice. To assess fibrosis, we performed Masson’s trichrome
staining and evaluated the expression of collagen 3 (Col3a1) and
Tgfb transcripts (Fig. 2, e and f). These measures together
showed that ISO triggered fibrosis-related parameters more
Masson’s trichrome staining. Magnification, 20×. Scale bar, 100 µm. Arrowheads show fibrotic areas (blue; P values are 0.0238, 0.0005, 0.0479). Results are
expressed as mean ± SEM; n = 6 mice/group. Data were analyzed by one-way ANOVA (*, P < 0.05; **, P < 0.001; ***, P < 0.0001, ****, P <0.00001 compared
with corresponding control [CT] mice; #, P < 0.05; ##, P < 0.001; ###, P < 0.0001 compared with corresponding WT mice).
Table 1. Echocardiographic data from 2-mo-old WT and Metrnβ−/− mice after ISO-induced hypertrophy
CT ISO
WT Metrnβ−/− WT Metrnβ−/− P value
HW/TL (mg/mm) 6.88 ± 0.16 7.32 ± 0.38 8.75 ± 0.33*** 8.59 ± 0.18** ****
HW/BW (mg/g) 4.10 ± 0.11 4.35 ± 0.12 5.20 ± 0.21*** 5.05 ± 0.20* ****
IVSd (mm) 0.57 ± 0.01 0.56 ± 0.01 0.60 ± 0.02 0.69 ± 0.01****,### ****, #, $$$
LVPWd (mm) 0.69 ± 0.03 0.67 ± 0.02 0.94 ± 0.08*** 0.78 ± 0.02# ***, #
LVIDd (mm) 4.21 ± 0.08 4.05 ± 0.13 4.14 ± 0.06 4.15 ± 0.04
IVSs (mm) 0.92 ± 0.03 0.88 ± 0.05 1.05 ± 0.06 1.22 ± 0.03***,# ****, $
LVPWs (mm) 0.93 ± 0.03 0.80 ± 0.02 1.23 ± 0.07*** 1.02 ± 0.03**,## ****, ##
LVIDs (mm) 3.08 ± 0.07 3.27 ± 0.04 2.96 ± 0.07 2.97 ± 0.03** **
EF (%) 59.3 ± 1.1 50.8 ± 2.1## 61.2 ± 1.2 62.3 ± 1.1**** ***, #, $$
FS (%) 27.2 ± 0.6 23.0 ± 0.7## 27.8 ± 0.8 28.8 ± 0.7**** ***, #, $$
EDV (mm3) 79.4 ± 3.5 77.7 ± 3.7 76.1 ± 2.7 76.28 ± 1.8
ESV (mm3) 37.5 ± 2.1 43.1 ± 1.2 34.1 ± 2.1 34.2 ± 0.9** **
Heart rate 308.2 ± 25.9 358.6 ± 28.9 474.6 ± 37.3*** 511.8 ± 11.22** ****
LVm (mg) 93.3 ± 2.4 84.2 ± 2.9 126.5 ± 11.3** 110.3 ± 4.0* **
Aortic peak (m/s) 1.11 ± 0.07 1.24 ± 0.06 1.39 ± 0.09* 1.54 ± 0.07* **
VTI (cm) 6.43 ± 0.53 6.56 ± 0.29 5.30 ± 0.65 5.70 ± 0.42
E peak (m/s) 1.09 ± 0.10 0.98 ± 0.10 1.18 ± 0.05 1.26 ± 0.06
Mitral deceleration (ms) 36.0 ± 2.7 30.2 ± 0.6 31.0 ± 1.8 27.3 ± 1.3 *, #
Aortic diameter (mm) 1.12 ± 0.02 1.20 ± 0.07 1.36 ± 0.01** 1.43 ± 0.07* ***
All measurements are expressed as mean ± SEM; n = 6 mice/group. Data were analyzed by two-way ANOVA, where *, P < 0.05, **, P < 0.001, ***, P < 0.0001,
****, P < 0.00001 for ISO effect; #, P < 0.05, ##, P < 0.001, ###, P < 0.0001 for genotype effect; $, P < 0.05, $$, P < 0.001, $$$, P < 0.0001 for interaction
effect. CT, control; d, after diastole; EDV, end diastolic volume; HW/BW, heart weight/body weight ratio; s, after systole.
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intensely inMetrnβ−/− mice than in WT mice in the septum, but
not in the LVPW. Moreover, we analyzed the expression levels
of negative regulators of apoptosis, such as Bcl-2, Bcl-xl, and
XIAP, in these animals (Fig. S2 a). At basal levels, we did not
observe significant differences due to genotype. After ISO
treatment, we found a significant increase in all genes—Bcl-2,
Bcl-xl, and XIAP—similar in both genotypes. These data suggest
an inhibition of the apoptotic processes due to ISO, regardless of
genotype.
Collectively, our findings indicate that the lack of Metrnβ
alters the heart, mostly promoting asymmetrical cardiac hy-
pertrophy characterized by left ventricular dysfunction and
enhancing interstitial fibrosis.
Finally, in order to confirm the role of Metrnβ favoring
asymmetrical cardiac hypertrophy, observed above in mice
lacking Metrnβ under the ISO induction model, we analyzed the
effects of Metrnβ invalidation in the aging-associated cardiac
remodeling process. For this purpose, we performed echocar-
diography assessments ofMetrnβ−/− andWTmice at two distinct
ages: 6 and 16 mo old (Table 2). We found that aging led to a
significant increase in LVPWd, IVS, LVID, end systolic volume
(ESV), and left ventricular mass (LVm) in both genotypes.
However, the increase in IVS, LVPW, and LVmwas significantly
higher in Metrnβ−/− mice compared with WT mice. Regarding
systolic function, we found a similar decrease in ejection frac-
tion (EF) over time in both genotypes. Aging led to a significant
increase in aortic diameter in both genotypes. However, aortic
diameter, aortic peak, and E peak were significantly increased in
16-mo-old Metrnβ−/− mice compared with their corresponding
age-matched WT mice; such a difference was already statisti-
cally significant for aortic diameter and E peak at the 6-mo-old
aging stage.
Collectively, these data confirmed the susceptibility of
Metrnβ−/− mice to spontaneously develop cardiac interventric-
ular hypertrophy and systolic and diastolic dysfunction in aging.
Cardiac-specific overexpression of Metrnβ prevents cardiac
hypertrophy development
To further investigate the function of Metrnβ in cardiac biology,
we set out to increase mouse Metrnβ expression specifically in
the heart. AAV9 is known to preferentially target the heart, and
specifically the cardiomyocytes, with minimal transduction of
other tissues and cell types (Bär et al., 2014). We found that,
under our experimental conditions of delivery in vivo, immu-
nohistochemical detection of enhanced GFP (eGFP) showed that
an AAV9 reporter vector (AAV9-CMV-eGFP) transduced higher
in heart cells than in cells in WAT, liver, or muscle (Fig. S1 b).
Specific AAV9-mediated expression of Metrnβ in the heart was
confirmed by our observations thatMetrnβ−/−mice injected with
AAV9-Metrnβ exhibited high Metrnβ transcript expression in
the heart, much lower expression in the skeletal muscle, and
almost no expression in the other analyzed tissues (Fig. S1 c). We
found that AAV-mediated targeting of Metrnβ expression in the
heart normalized (and even increased) circulating Metrnβ levels
Table 2. Echocardiographic data from 6- and 16-mo-old WT and Metrnβ−/− mice
6 mo old 16 mo old
WT Metrnβ−/− WT Metrnβ−/− P value
IVSd (mm) 0.57 ± 0.01 0.72 ± 0.03# 0.64 ± 0.01 0.85 ± 0.06## *, ###
LVPWd (mm) 0.59 ± 0.03 0.71 ± 0.02# 0.68 ± 0.01 0.69 ± 0.02 #
LVIDd (mm) 4.37 ± 0.02 4.30 ± 0.11 4.41 ± 0.06 4.58 ± 0.12
IVSs (mm) 0.98 ± 0.02 1.12 ± 0.04# 1.06 ± 0.01 1.32 ± 0.04**,### **, ####
LVPWs (mm) 0.82 ± 0.03 0.91 ± 0.03 0.80 ± 0.02 0.84 ± 0.03 #
LVIDs (mm) 3.21 ± 0.11 3.30 ± 0.15 3.52 ± 0.05 3.60 ± 0.12 *
EF (%) 58.2 ± 3.7 53.8 ± 2.8 47.0 ± 0.4* 49.4 ± 2.1 **
FS (%) 26.5 ± 2.4 23.8 ± 1.7 20.0 ± 0.4* 21.2 ± 1.1
EDV (mm3) 86.4 ± 1.2 83.6 ± 5.2 88.5 ± 3.1 96.7 ± 5.7
ESV (mm3) 41.76 ± 3.6 44.65 ± 4.7 51.79 ± 1.7 55.0 ± 4.4 *
Heart rate 337.3 ± 17.4 352.6 ± 17.2 381.3 ± 18.6 382.6 ± 12.0 *
LVm (mg) 89.9 ± 2.2 113.4 ± 6.4# 107.1 ± 1.8 148.1 ± 8.6**,### ***, ####
Aortic peak (m/s) 1.02 ± 0.06 0.90 ± 0.03 0.84 ± 0.04 1.07 ± 0.05*## $$
VTI (cm) 5.72 ± 0.52 5.00 ± 0.19 4.60 ± 0.23 5.14 ± 0.23
E peak (m/s) 0.78 ± 0.06 0.91 ± 0.06 0.83 ± 0.01 0.98 ± 0.05 #
Mitral deceleration (ms) 26.7 ± 2.1 27.4 ± 1.6 23.7 ± 1.3 26.6 ± 1.7
Aortic diameter (mm) 1.15 ± 0.01 1.23 ± 0.03 1.24 ± 0.01 1.32 ± 0.05 *, #
All measurements are expressed as mean ± SEM; n = 5 mice/group. Data were analyzed by two-way ANOVA, where *, P < 0.05, **, P < 0.001, ***, P < 0.0001
for 16-mo-old effect; #, P < 0.05, ##, P < 0.001, ###, P < 0.0001, ####, P < 0.00001 for genotype effect; $$, P < 0.001 for interaction effect. d, after diastole;
EDV, end diastolic volume; s, after systole.
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in Metrnβ−/− mice (Fig. S1 d), which supports the notion that
heart-originating Metrnβ can affect circulating systemic levels.
Since Metrnβ is expressed in many tissues in the body, to
elucidate the role of cardiac-originated Metrnβ, we overex-
pressed Metrnβ in the myocardium ofMetrnβ−/− mice.Metrnβ−/−
mice were injected with AAV9 vectors preferentially targeting
cardiomyocytes, AAV9-null (used as control vector) or AAV9-
Metrnβ and were continuously infused with ISO for 7 d to in-
duce cardiac hypertrophy (Fig. 3). As expected, after 7 d of ISO
infusion, the HW/TL ratio was significantly increased in AAV9-
null–injected Metrnβ−/− mice compared with non–ISO-treated
Metrnβ−/− mice. In contrast, the HW/TL ratio (indicative of the
development of cardiac hypertrophy) was significantly reduced
in Metrnβ−/− mice in which Metrnβ expression in the heart has
been induced by AAV9-Metrnβ injection (Fig. 3 a). No difference
in blood pressure was found under the conditions tested (Table
S2). Histological examination of H&E-stained LVPW and septum
tissue sections confirmed that the CSA was significantly smaller
in ISO-treated Metrnβ−/− mice injected with AAV9-Metrnβ than
in corresponding ISO-treated Metrnβ−/− mice injected with
AAV9-null vector (Fig. 3, b and c). The effects were especially
marked in the septum, where CSA increase due to ISO was fully
prevented by AAV9-Metrnβ–mediated delivery.
Echocardiographic parameters (Table 3) revealed that ISO
increased IVS, LVPW, and LVm in both conditions, as expected.
However, the LVm calculated by echocardiography and IVS was
significantly reduced in ISO-treated AAV9-Metrnβ–injected
mice compared with the corresponding AAV9-null–injected
mice, indicating that the former mice had undergone rever-
sion of cardiac hypertrophy. EF and FS were similarly increased
after ISO treatment in both conditions, but the aortic peak and
velocity time integral (VTI) were significantly decreased in
AAV9-Metrnβ–injected mice.
The expression of the cardiac hypertrophy marker genes
Nppa and Acta1 was similar in Metrnβ−/− mice, irrespective of
injection with AAV9-Metrnβ or the AAV9-null control vector
(Fig. 3 d). However, ISO infusion increased the mRNA expres-
sion levels of Nppa and Acta1 in AAV9-null–injected mice, but
this effect was significantly blunted in ISO-treated AAV9-
Metrnβ–injected mice. We also found that ISO led to a sub-
stantial increase in fibrosis (as assessed by Masson’s trichrome
staining) and concomitant expression of Col3a1 and Tgfb in
AAV9-null–injected Metrnβ−/− mice, but not in AAV9-
Metrnβ–injected mice (Fig. 3, e and f).
Based on these findings, we conclude that cardiac over-
expression of Metrnβ prevents cardiac hypertrophy and fibrosis
in Metrnβ−/− mice in an autocrine manner.
Next, we performed the same experiment in WT mice in-
jected with AAV9-null or AAV9-Metrnβ and infused with ISO
for 7 d to induce cardiac hypertrophy (Fig. 3 g). HW/TL ratio was
significantly increased by ISO in both AAV9-null– and AAV9-
Metrnβ–injected mice compared with their corresponding
controls. However, HW/TL ratio was significantly reduced in
AAV9-Metrnβ–injected WT mice compared with their corre-
sponding AAV9-null–injected mice subjected to ISO. Echocar-
diographic measurements showed a significant increase in LVm,
IVSd, LVPWd, and aortic peak in AAV9-null–injected mice
subjected to ISO but not in AAV9-Metrnβ–injected mice. The
mRNA expression levels of Nppa were significantly induced by
ISO in AAV9-null–injected mice and significantly reduced in
AAV9-Metrnβ–injected mice. Finally, ISO led to an increased
expression of Col3a1 in AAV9-null–injected WT mice and in
AAV9-Metrnβ–injected mice. However, Col3a1 mRNA levels
were significantly lower in AAV9-Metrnβ–injected mice.
These data indicate that cardiac overexpression of Metrnβ
also prevents cardiac hypertrophy and fibrosis development
in WT mice.
Metrnβ induces the gene programs of fatty acid oxidation
(FAO) and alternatively activated (M2) macrophages in cardiac
tissue in vivo
Given that there is a close association between impaired FAO
and cardiac hypertrophy (Smeets et al., 2008a; Planavila et al.,
2005b), we examined the expression of FAO-related genes. The
transcript levels of pyruvate dehydrogenase kinase-4 (Pdk4),
carnitine palmitoyltransferase (Cpt1b), medium-chain acyl-CoA
dehydrogenase (Acadm), and PPARγ coactivator-1α (PGC1-α,
Ppargc1a) were markedly decreased in AAV9-null–injected
Metrnβ−/− mice after ISO treatment, as expected (Fig. 4 a).
AAV9-Metrnβ vector–mediated overexpression ofMetrnβ in the
heart led to a significant up-regulation of Pdk4 and Ppargc1a
transcript levels in the heart. Moreover, the protein levels of
PGC1-α were significantly increased in cardiac tissue of mice
overexpressing Metrnβ (Fig. 4 b).
Overall, these findings indicate that overexpression of
Metrnβ and subsequent cardiac hypertrophy reversion are as-
sociated with activation of the PGC1-α and FAO pathways.
Given these findings, we analyzed the expression levels of
FAO-related genes in the Metrnβ−/− mice compared with WT
mice (Fig. 4). We found that the expression levels of FAO-related
genes were greatly reduced in Metrnβ−/− mice under both basal
and ISO-exposed conditions compared with WT mice (Fig. 4 c).
Considering that a proinflammatory status is often associated
with cardiac hypertrophy development, and considering that it
has been reported that Metrnβ modulates systemic and adipose
tissue inflammatory pathways in different ways (Rao et al., 2014;
Ushach et al., 2018), we next assessed the expression levels of
genes involved in proinflammatory type 1 cytokine signaling,
such as Il6, MCP-1 (Ccl2), and TNFα (Tnfa), in the hearts of
Metrnβ-overexpressing mice (Fig. 4 d). We found that ISO in-
duced Il6, Ccl2, and Tnfα in AAV9-null–injectedMetrnβ−/− hearts
but not in AAV9-Metrnβ–injectedMetrnβ−/− hearts, in which the
expression levels of Ccl2 and Tnfα were significantly reduced.
Next, we analyzed the mRNA levels of anti-inflammatory genes
associated with type 2 cytokine signaling, such as Arg1, Cd163,
and Mrc1 (Fig. 4 e). We found that cardiac Metrnβ over-
expression up-regulated the transcript levels of these genes and,
more important, that the ratio M1/M2 macrophages estimated
on the basis of the iNOS/Arg1 ratio (Redondo-Angulo et al., 2016;
Cereijo et al., 2018) was significantly down-regulated in the
hearts of Metrnβ-overexpressing mice (Fig. 4 f). Finally, im-
munostaining of total macrophages (F4/F80-positive cells) in
these hearts indicated that there was no difference in the total
macrophage population under any of the tested conditions
Rupérez et al. Journal of Experimental Medicine 7 of 18
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Figure 3. Metrnβ prevents the development of cardiac hypertrophy in vivo. (a–f) 2-mo-oldMetrnβ−/− mice were injected i.p. with AAV9 carrying Metrnβ
(AAV9-Metrnβ; blue bars) or AAV9-null (white bars) and were continuously infused with ISO for 7 d to induce cardiac hypertrophy. (a) HW/TL ratio (P values
are 0.0023, 0.001, 0.0053). (b) Quantification of cardiomyocyte CSA in the LVPW and the septum (S; P values are 0.0225, 0.0067, 0.0148, 0.0138, 0.0328,
0.0143). (c) Representative histological sections of hearts stained with H&E, which were used to determine cardiomyocyte CSA. Magnification, 20×. Scale bar,
50 µm. (d) mRNA expression of the hypertrophy markers Nppa and Acta1 in the heart (P = 0.0006). (e) mRNA expression levels of the fibrosis markers Col3a1
and Tgfb (P values are <0.0001, <0.0001, 0.0312, 0.0198). (f) Determination of fibrosis in histological sections by Masson’s trichrome staining. Magnification,
20×. Scale bar, 100 µm. Arrowheads show fibrotic areas (blue; P values are 0.0137, 0.0365, 0.0088). (g) 2-mo-old WT mice were injected i.p. with AAV9
carrying Metrnβ (AAV9-Metrnβ; green bars) or AAV9-null (gray bars) and were continuously infused with ISO for 7 d to induce cardiac hypertrophy. HW/TL
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(Fig. 4 g). Since eosinophils have been reported as targets of
Metrnβ in adipose tissue (Rao et al., 2014), we next studied the
expression of the genes encoding Il4 and Il13, which are pro-
duced by eosinophils, among other cell types, in the hearts of
these mice; however, we were unable to detect any significant
expression of Il4 or Il13 under any of the tested conditions. Al-
together, these data indicate that Metrnβ does not generate a
massive change in the total amount of macrophages in the heart,
but rather induces a shift toward a noninflammatory environ-
ment in the myocardium.
Finally, we analyzed the inflammatory genes in the model of
Metrnβ−/− mice. We found that although the proinflammatory
genes Il6,MCP-1 (Ccl2), and TNFα (Tnfa) were up-regulated upon
ISO treatment regardless of genotype (Fig. 4 h), the genes en-
coding anti-inflammatory type 2 cytokine signaling components
were up-regulated in WT mice but not in Metrnβ−/− mice after
hypertrophy induction (Fig. 4 i).
Metrnβ directly targets cardiac cells and prevents
cardiomyocyte hypertrophy
To establish whether the effects of Metrnβ observed in our
in vivo studies involve a direct action ofMetrnβ on cardiomyocytes,
we used primary cultured NCMs for experiments in vitro. We
investigated the effects of Metrnβ using the standard PE treat-
ment model to induce cardiac cell hypertrophy. PE treatment
increased CSA (an indication of cell hypertrophy), whereas
Metrnβ significantly attenuated this PE-induced cell enlarge-
ment (Fig. 5, a and b). The transcript levels of the molecular
markers of hypertrophy, Nppa and Acta1, were increased in as-
sociation with PE-induced hypertrophy, and this effect was re-
duced by treatment with Metrnβ. Moreover, overexpression of
Metrnβ via Ad-mediated transduction prevented the PE-induced
hypertrophy of these cells (Fig. 5, c and d). Furthermore, we
found that in PE-induced hypertrophy in which NCMs were
additionally treated with proinflammatory factors (TNFα or
LPS), overexpression of Metrnβ retained its capacity to prevent
hypertrophy development (Fig. S2 b).
As reported previously (Ferrer-Curriu et al., 2019; Teunissen
et al., 2007), rat CFs cultured on a rigid substrate show pro-
gressive fibroblast-to-myofibroblast differentiation, such that
passage 1 (P1) cells are considered CFs and P3 cells are consid-
ered cardiac myofibroblasts (CMFs) based on the marked in-
crease in α-smooth muscle actin (α-SMA, Acta2). We confirmed
that the mRNA and protein levels of α-SMA (Acta2) were
ratio, LVm, IVS dimension, LVPW, and LVID after diastole (IVSd, LVPWd, and LVIDd, respectively), aortic (A) peak, and mRNA expression levels of Nppa and
Col3a1. Values are expressed as fold induction (ISOmice versus their corresponding control mice). (P values are 0.0294, 0.032, 0.0032, 0.0215, 0.0088, 0.0265,
0.0002, <0.0001, 0.0011). n = 5 mice/group. Results are expressed as mean ± SEM; data were analyzed by one-way ANOVA (*, P < 0.05 compared with
corresponding control [CT] mice; #, P < 0.05 compared with corresponding AAV9-null mice).
Table 3. Echocardiographic data from Metrnβ−/− mice injected with AAV9-Metrnβ or AAV9-null after ISO-induced hypertrophy
CT ISO
AAV-null AAV-Metrnβ AAV-null AAV-Metrnβ P value
IVSd (mm) 0.59 ± 0.3 0.53 ± 0.3 0.87 ± 0.04*** 0.76 ± 0.04** ****, #
LVPWd (mm) 0.64 ± 0.02 0.66 ± 0.04 0.85 ± 0.04** 0.80 ± 0.04 ***
LVIDd (mm) 4.34 ± 0.3 4.26 ± 0.16 4.55 ± 0.08 4.30 ± 0.13
IVSs (mm) 1.02 ± 0.04 0.80 ± 0.06# 1.48 ± 0.07**** 1.25 ± 0.02***,# ****, ###
LVPWs (mm) 0.76 ± 0.02 0.84 ± 0.05 1.11 ± 0.05*** 1.15 ± 0.09** ****
LVIDs (mm) 3.23 ± 0.27 3.41 ± 0.17 3.24 ± 0.13 3.15 ± 0.19
EF (%) 57.4 ± 2.7 47.2 ± 3.3 61.7 ± 3.3 59.0 ± 4.1 *
FS (%) 26.0 ± 1.7 20.4 ± 1.7 28.8 ± 2.1 27.0 ± 2.5 *
EDV (mm3) 87.5 ± 13.8 81.9 ± 7.2 95.1 ± 4.3 83.4 ± 6.1
ESV (mm3) 43.9 ± 9.0 48.4 ± 5.8 42.8 ± 4.2 40.2 ± 5.5
Heart rate 392.6 ± 27.1 292.6 ± 28.1## 485.2 ± 8.8** 453.4 ± 12.9**** ****, ##
LVm (mg) 108.6 ± 10.1 88.2 ± 5.3 164.3 ± 2.9** 123.8 ± 16.3*,# ***, ##
Aortic peak (m/s) 1.08 ± 0.04 0.76 ± 0.07## 1.21 ± 0.06 0.89 ± 0.05## *, ####
VTI (cm) 4.66 ± 0.27 4.08 ± 0.55 4.93 ± 0.44 3.60 ± 0.42 #
E peak (m/s) 0.78 ± 0.04 0.68 ± 0.05 0.88 ± 0.09 0.86 ± 0.07
Mitral deceleration (ms) 27.0 ± 3.1 27.4 ± 1.5 25.2 ± 1.5 29.5 ± 1.9
All measurements are expressed as mean ± SEM; n = 5 mice/group. Data were analyzed by two-way ANOVA, where *, P < 0.05, **, P < 0.001, ***, P < 0.0001,
****, P < 0.00001 for ISO effect; #, P < 0.05, ##, P < 0.001, ###, P < 0.0001, ####, P < 0.00001 for AAV9-Metrnβ effect. d, after diastole; EDV, end diastolic
volume; s, after systole.
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Figure 4. Fatty acid metabolism, inflammatory signals in heart, and the effects of Metrnβ. 2-mo-old Metrnβ−/− mice were injected i.p. with AAV9
carrying Metrnβ (AAV9-Metrnβ; blue bars) or AAV9-null (white bars; a, b, d–g; n = 5 mice/group), or WT littermates (gray bars) andMetrnβ−/− (white bars) mice
(c, h, i; n = 6 mice/group) were continuously infused with ISO for 7 d. (a)mRNA expression levels of the lipid catabolism genes Pdk4, Cpt1b, Acadm, and Ppargc1a
(P values are 0.001, 0.0437, 0.0475, 0.0321, 0.0018, 0.0029, 0.0327, 0.0019). (b) PGC1α protein levels in cardiac tissue (P values are <0.0001, 0.0005).
(c)mRNA expression levels of Pdk4, Cpt1b, Acadm, and Ppargc1a (P values are 0.01, 0.0044, 0.0363, 0.0385, 0.0009, 0.0037). (d)mRNA expression levels of the
proinflammatory genes Il6, Ccl2, and Tnfa (P values are <0.0001, <0.0001, 0.0026, 0.0011, 0.0393, 0.0136, 0.0069). (e) mRNA expression levels of the anti-
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increased in P3 cells compared with P1 cells (Fig. 5 e). Treatment
of CFs and CMFs with Metrnβ did not modify the mRNA ex-
pression and protein levels of α-SMA in CFs or CMFs, indicating
that Metrnβ does not have any direct, cell-autonomous effect on
cardiac fibrosis in this in vitro model.
Collectively, these data indicate thatMetrnβ has direct effects
on cardiomyocytes and protects against cardiac hypertrophy and
inflammation but does not directly target CFs.
Metrnβ as a cardiokine: Autocrine actions of Metrnβ on
cardiac cells
Considering the duality of cardiac cells as both a target and a
source of Metrnβ, we examined whether this factor could play
an autocrine role (Fig. 5, f and g) by incubating NCMs with an
anti-Metrnβ neutralizing antibody. The addition of an Metrnβ-
neutralizing antibody to the NCM culture medium significantly
increased the CSA of cardiomyocytes and the expression levels
of the hypertrophy marker genes Nppa and Acta1. During the PE-
induced enhancement of cardiac hypertrophy, we observed a
non-significant tendency for further enhancement of Nppa
mRNA expression. Taken together, these findings indicate that
blocking the activity of endogenously released Metrnβ favors an
enhanced hypertrophic state in cardiac cells, thereby confirming
an autocrine role for cardiomyocyte-secreted Metrnβ.
Finally, although there is no current knowledge on the
identity of cellular receptor(s) for Metrnβ, we explored the in-
tracellular molecular pathway by which Metrnβ may act on
cardiac cells. We determined the effects of Metrnβ on a set of
putative intracellular kinase-mediated signaling pathways using
a multiplex system (Fig. 5 h and Fig. S1 e). We found two pro-
teins involved in intracellular signaling whose phosphorylation
status was induced in response to Metrnβ in NCMs: p38-MAPK
and the transcription factor CREB (cAMP response element
binding). We confirmed phosphorylation of both proteins, p38-
MAPK and CREB, in response to Metrnβ in NCMs by Western
blot analysis (Fig. 5 h). We also found that the expression of the
gene encoding PGC1α, which is a known target of both p38-
MAPK and CREB phosphorylation in other cell systems
(Villarroya et al., 2018), was induced in response to Metrnβ
treatment in cultured cardiomyocytes (Fig. 5 i). Collectively,
these findings indicate that, in cardiac cells, Metrnβ directly
activates the p38-MAPK and CREB intracellular pathways,
which are upstream of the transcriptional regulation of PGC1α.
Metrnβ is a new prognostic biomarker for human HF
Finally, considering that Metrnβ is a secreted protein and that
altered levels of cardiokines have been previously proposed as
biomarkers of cardiac damage (Bayes-Genis et al., 2012; Bayés-
Genı́s et al., 2015; Lupón et al., 2013), we next explored the value
of Metrnβ as a new potential prognostic biomarker in HF. First,
we determined the plasma levels of Metrnβ in patients over age
(<60 yr old, mean age 45 ± 1.35 [26–60], n = 33; >60 yr old, mean
age 80 ± 1.48 [70–96], n = 23; Fig. 6 a). We found that aging led to
a significant reduction in Metrnβ circulating levels. Next, we
determined Metrnβ circulating levels in control (n = 56; mean
age 60 ± 2.63) and HF patients (n = 49; mean age 67 ± 1.7). We
found that Metrnβ circulating levels were significantly in-
creased in patients suffering from HF compared with controls
(Fig. 6 b). Finally, we examined the predictive value of circu-
lating Metrnβ in a large cohort of 446 patients with HF (mean
age, 66.7 yr [59–76], 72.4% male, and median LVEF of 34.8%) to
assess mortality risk (Table S3). In a comprehensive multivari-
able analysis (Table 4) that included Metrnβ, age, sex, LVEF,
ischemic etiology, and the presence of diabetes and hyperten-
sion, only Metrnβ (hazard ratio [HR], 1.175; 95% confidence in-
terval [CI], 1.009–1.369; P = 0.038), age (HR, 1.055; 95% CI,
1.039–1.071; P < 0.001), and sex (HR, 0.690; 95% CI, 0.483–0.985;
P = 0.041) were found to be independent predictors of all-cause
death. Interestingly, only age (HR, 1.05; 95% CI, 1.03–1.07; P <
0.001), Metrnβ (HR, 1.12; 95% CI, 1.08–1.71; P = 0.008), and is-
chemic etiology (HR, 1.70; 95% CI, 1.10–2.65; P = 0.018) were
found to be independent predictors of cardiovascular death. In
the sensitivity analysis, Metrnβ expressed as quartiles retained
independent prognostic value (Table 4). Harrell’s C-statistics for
the multivariable model including Metrnβ were 0.71 (95% CI,
0.67–0.75) and 0.73 (95% CI, 0.68–0.78) for all-cause and car-
diovascular death, respectively. These data indicate that Metrnβ
is a promising, powerful new prognostic biomarker for HF.
Discussion
In the present study, we identify Metrnβ as a novel cardiokine,
as summarized in Fig. 6 c. We show that the heart is a source of
expression and release of Metrnβ as well as a target of Metrnβ.
Moreover, we found that Metrnβ exerts a cardioprotective ac-
tion. Thus, the absence of Metrnβ is associated with cardiac
alterations, including asymmetrical hypertrophy, fibrosis, and
cardiac dysfunction. Reciprocally, cardiac-specific overexpression
of Metrnβ prevents the development of cardiac hypertrophy
and fibrosis and restores the normal functioning of the myo-
cardium. Metrnβ can act directly in cardiac cells to protect
against hypertrophic processes in mice. In humans, who also
express high levels of Metrnβ in the heart, Metrnβ appears to
be a strong biomarker of HF prognosis. Overall, our study is the
first to show that Metrnβ in the myocardium plays a key role in
cardiac pathophysiology.
Our data show that the absence of Metrnβ causes develop-
ment of an abnormal pattern of asymmetric hypertrophy, with
inflammatory genes Arg1, Cd163, andMrc1 (P values are 0.0064, 0.0004, 0.0023, 0.0263, 0.0051). (f)M1/M2 macrophage ratio, which was defined as the iNos/
Arg1 expression level ratio (Student’s t test; P = 0.0452). (g)Macrophages stained with an anti-F4/80 antibody in the heart, assessed by immunofluorescence.
Magnification, 20×. Scale bar, 50 µm. (h) mRNA expression levels of the proinflammatory genes Il6, Ccl2, and Tnfa (P values are <0.001, 0.0098, 0.0007,
0.0069). (i) mRNA expression levels of the anti-inflammatory genes Arg1, Cd163, and Mrc1 (P values are 0.0007, 0.0167, 0.0244, 0.0083, 0.0054). Results are
expressed as mean ± SEM; data were analyzed by one-way ANOVA (*, P < 0.05 compared with corresponding control [CT] mice; #, P < 0.05 compared with
corresponding AAV9-null [a, b, d-g] mice or WT mice [c, h, i]).
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Figure 5. Effects of Metrnβ on cardiomyocytes: protection against PE-induced hypertrophy in an autocrine manner. (a and b) Cardiomyocyte size (a;
CSA; data are representative of three independent experiments; P values are 0.0007, 0.0039, 0.0097, 0.0143, 0.0307, 0.0437) and mRNA expression levels (b)
of the hypertrophy markers Nppa and Acta1 in NCMs after PE-induced hypertrophy alone or with Metrnβ pretreatment for 24 h at different concentrations
(data are representative of three independent experiments; P values are <0.0001, <0.0001, 0.0051, 0.0153, <0.0001, <0.0001). (c and d) Cardiomyocyte size
(c; CSA; data are representative of three independent experiments; P values are 0.016, 0.0169) and mRNA expression levels [d] of the hypertrophy markers
Nppa and Acta1 in NCMs overexpressing Metrnβ (Ad-Metrnβ; blue bars) or Ad-null control vector (Ad-null; gray bars) at 10 IFU/cell and treated with PE for 24 h
(data are representative of three independent experiments; P values are 0.0037, 0.0108, 0.0421, 0.0327, 0.0082). (e) α-SMA (Acta2) expression levels in
Metrnβ (0.5 µg/ml)-treated primary culture CFs at P1 and P3 (data are representative of three independent experiments; P values are 0.002, 0.0065). (f and g)
Cardiomyocyte size (f; CSA; data are representative of two independent experiments; P values are both <0.0001) and mRNA expression levels (g) of the
hypertrophy markers Nppa and Acta1 in NCMs treated with anti-Metrnβ antibody or control anti-IgG antibody added to the culture medium in the presence or
Rupérez et al. Journal of Experimental Medicine 12 of 18
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the most severe hypertrophy involving the basal IVS, interstitial
fibrosis, aortic dilation, and left ventricular dysfunction. This
phenotype, which shows a patternmore characteristic of cardiac
dysfunction than of non-asymmetrical hypertrophy, resembles
that in patients with hypertrophic cardiomyopathy (Marian
and Braunwald, 2017; Yousefzai et al., 2017), one of the leading
causes of sudden death among young people (Maron andMaron,
2013). Although it has been shown that hypertrophic cardio-
myopathy may be inherited (Katayama et al., 2018), it seems
unlikely that the effects observed in our global KO model are
early development related, since basal signs of cardiac hyper-
trophy do not develop spontaneously in young Metrnβ-null
mice. However, we cannot completely rule out this possibility,
because Metrnβ has been reported to have effects on neuro-
nal growth and brain development during embryogenesis
(Jørgensen et al., 2012). Moreover, the abnormal hypertrophic
response observed in Metrnβ-null mice is highly consistent,
since it develops both after drug-induced hypertrophy and
during the natural development of hypertrophy associated with
aging. Nevertheless, we recognize the limitations of using a
global Metrnβ−/− mouse model in terms of attributing cardiac
alterations to the heart-specific loss of Metrnβ. Moreover, be-
causeMetrnβ−/− mice fully develop despite the complete absence
of the cytokine, these global KO mice may be viewed as an ex-
treme model of Metrnβ function that also is unable to fully
distinguish between developmental/aging and physiological
effects.
The evidence that Metrnβ is cardioprotective may be viewed
at first glance as paradoxical, given that we found high Metrnβ
levels associated with cardiac pathology in humans and in
mouse models. These high Metrnβ levels may be a reactive
process to heart damage, which do not achieve full protection.
Similar observations have beenmade for other cardiokines, such
as ANF and FGF21 (Planavila et al., 2017; Planavila et al., 2013),
which would share with Metrnβ protective actions upon the
heart and high levels in cardiac pathology. The positive rela-
tionship between high levels of Metrnβ and cardiovascular
death in our analysis of the prognostic value of Metrnβ levels is
consistent with this scenario.
Although Metrnβ shows remarkable expression in the heart,
its expression in the pericardium, skin, colon, trachea, tongue,
and other mucosal sites is known to be much higher, suggesting
a role for Metrnβ in native immunity (Ushach et al., 2015). In
fact, Metrnβ expression has also been linked to inflammatory
diseases, such as psoriasis, psoriatic and rheumatoid arthritis,
and possibly sepsis (Ushach et al., 2015; Bridgewood et al., 2019).
absence of PE (data are representative of two independent experiments; P values are 0.0015, 0.0181, 0.0002, 0.011, 0.0182). (h) Phosphorylation levels
determined by Milliplex (left) and Western blot (right) of CREB and p38 in NCMs treated with Metrnβ (0.5 µg/ml) for different durations (data are repre-
sentative of three independent experiments; P values are 0.0336, 0.0066). (i) Ppargc1a (PGC1α) expression levels in NCMs treated with different concen-
trations of Metrnβ for 24 h (data are representative of three independent experiments; P = 0.0007). Results are expressed as mean ± SEM. Data were analyzed
by Student’s t test (*, P < 0.05 compared with control cells; #, P < 0.05 compared with PE-treated or corresponding controls).
Figure 6. Circulating levels of Metrnβ are regulated in humans. (a)
Plasma levels of Metrnβ in humans <60 yr old (mean age, 45 ± 1.35; n =
33) and >60 yr old (mean age, 80 ± 1.48; n = 23; P < 0.0001). (b) Plasma
levels of Metrnβ in control (mean age, 60 ± 2.63; n = 56) and HF (mean
age, 67 ± 1.7; n = 49) patients (P = 0.0093). Results are expressed as
mean ± SEM. Data were analyzed by nonparametric Mann-Whitney
test; **, P <0.001; ***, P < 0.0001 versus control patients. (c) Sche-
matic representation of the transcriptional regulation and the endocrine
and autocrine/paracrine actions of Metrnβ in the myocardium.
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Consistent with this, Metrnβ−/− mice are more susceptible to
septic shock and develop inflammatory lesions with aging
(Ushach et al., 2018). An increase in the levels of Metrnβ in HF
patients is consistent with this scenario, since inflammation is
highly induced in HF patients. Moreover, Metrnβ levels are
reduced in aging; thus, perhaps this low Metrnβ tone may con-
fer an increased susceptibility to inflammation in the aged
condition.
We found that the expression of Metrnβ in the heart is
powerfully regulated by PPARα, which is in agreement with the
cardioprotective role of Metrnβ. PPARα is known to strongly
protect against heart damage, such as by blunting cardiac hy-
pertrophy (Planavila et al., 2011; Smeets et al., 2008a), and the
induction of Metrnβ may be one mechanism by which PPARα
exert its protective actions.
In addition to the protective role of systemic Metrnβ on the
heart, our data indicate that the local secretion of Metrnβ in the
context of cardiac damage may serve as an endogenous autor-
egulatory means of cardioprotective signaling either in vitro or
in vivo. Thus, the ability of Metrnβ-targeting antibodies to
suppress the action of Metrnβ in cardiac cell cultures indicates
that Metrnβ can act in an autocrine manner to protect car-
diac cells from hypertrophic insults. Furthermore, the anti-
hypertrophic effect of cardiac Metrnβ overexpression, mainly
expressed in cardiomyocytes, in Metrnβ−/− mice also supports
an autocrine capacity for this cardiokine.
The identity of the cellular receptor(s) mediating Metrnβ
action is currently unknown. In cardiomyocytes, we herein re-
veal for the first time that Metrnβ treatment leads to the in-
tracellular induction of p38-MAPK and to the phosphorylation of
the transcription factor CREB, in contrast with findings in
macrophages showing preferential induction of STAT3 phos-
phorylation by Metrnβ (Baht et al., 2020; Rao et al., 2014). Our
observation that Metrnβ induces PGC1α in the heart both in vivo
and in vitro is consistent with the known role of p38-MAPK
induction and CREB phosphorylation in other cell systems,
such as brown adipocytes (Villarroya et al., 2018). Our findings
are also consistent with the known role of PGC1α as a car-
dioprotective actor (Aubert et al., 2013; Leone et al., 2005; Huss
and Kelly, 2004) and with reports indicating that inactivation of
p38-MAPK elicits cardiac hypertrophy in vivo (Braz et al., 2003).
However, there is controversy regarding the general roles of
p38-MAPK (Braz et al., 2003; Clerk et al., 1998) and CREB (Chien
et al., 2015; Watson et al., 2007) activation in cardiac hyper-
trophy, and some reports have indicated that activation of p38-
MAPKmay promote cardiac hypertrophy (Streicher et al., 2010).
It is worth mentioning that although we found that Metrnβ
has direct actions on cardiomyocytes, its protective effects in
heart experimental models in vivo appear to involve a complex
pattern of modifications, including the promotion of a nonin-
flammatory environment in the myocardium. The involvement
of Metrnβ in promoting anti-inflammatory effects is consistent
with previous reports demonstrating that Metrnβ triggers in-
creased M2 macrophage polarization in adipose tissues (Rao
et al., 2014) and increases recruitment of immune cells to in-
jured skeletal muscle (Baht et al., 2020). We also observed that
Metrnβ reduced cardiac fibrosis in vivo but did not find that
Metrnβ had any direct effect on CFs. Further research is needed
to establish a comprehensive profile of the paracrine actions of
cardiomyocyte-originating Metrnβ on the distinct cell types
present in the heart, in addition to the autocrine effects on
cardiomyocytes identified here. Moreover, further research will
Table 4. Prognostic value of Metrnβ as a new biomarker for HF patients
All-cause death Cardiovascular death
HR 95% CI P value HR 95% CI P value
Age, yr 1.06 1.04–1.07 <0.001 1.05 1.03–1.07 <0.001
Female 0.69 0.48–0.99 0.041 0.86 0.67–1.49 0.600
ZLog (Metrnl) 1.18 1.01–1.37 0.038 1.12 1.08–1.71 0.008
LVEF 1.01 1.00–1.02 0.191 1.00 0.99–1.02 0.720
Ischemia 1.07 0.79–1.46 0.646 1.70 1.10–2.65 0.018
Diabetes 1.33 0.99–1.80 0.062 1.26 0.82–1.93 0.300
Hypertension 1.06 0.75–1.48 0.758 1.03 0.62–1.71 0.920
Quartile
Age, yr 1.05 1.04–1.07 <0.001 1.05 1.23–1.68 0.001
Female 0.69 0.48–0.99 0.043 1.00 0.97–1.02 0.650
ZLog (Metrnl) 1.26 1.09–1.45 0.002 1.46 1.23–1.68 0.001
LVEF 1.01 1.00–1.02 0.171 0.86 0.31–1.41 0.600
Ischemia 1.06 0.78–1.44 0.711 1.66 1.21–2.11 0.027
Diabetes 1.32 0–98–1.77 0.072 1.25 0.83–1.66 0.310
Hypertension 1.03 0.73–1.44 0.875 0.98 0.48–1.47 0.920
Multivariable analysis of cohort data of HF patients was performed following the Fine and Gray method from R essentials for SPSS. Values of Metrnβ were
available for all patients and were log-transformed. ZLog, log-transformed and per 1 SD.
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also be needed to fully establish how much heart-derived
Metrnβ contributes to the systemic levels of this protein, since
some effects could also come frommuscle secretion as well. This
would allow us to identify a potential endocrine role of Metrnβ
as a cardiokine and determine a biological rationale for assessing
circulating Metrnβ levels in relation to cardiac pathology in
patients.
Our identification of Metrnβ as a novel cardiokine has rele-
vant biomedical implications. From a therapeutic viewpoint, our
data indicate that long-term cardiac Metrnβ overexpression
driven by the AAV9 subtype, with high cardiac tropism, could
deserve future research as a potential gene therapy strategy
against cardiac disease. However, although preferential ex-
pression in the heart, some AAV9-driven expression at other
tissues, as shown here for muscle or in neural tissue according to
Foust et al. (2009), may be a limitation. In any case, AAV-
mediated gene therapy has an excellent record of efficacy and
safety in vivo; in 2012, the European Union approved the first
AAV-mediated in vivo gene therapy product, Glybera (alipogene
tiparvovec), and others are currently in the pipeline (Büning,
2013). Moreover, based on data obtained from a large human
cohort, we provide the first report indicating that Metrnβ has
strong potential as a biomarker of heart disease.
In summary, our study indicates that Metrnβ shows promise
as a new potential therapeutic agent for cardiac diseases and also




EM:07966) were obtained from the Wellcome Trust Sanger In-
stitute Mouse Genetics Project. Pparα-null mice (B6.129S4-
Pparatm1Gonz/J) were obtained from The Jackson Laboratory. WT
littermates were used as controls for all experiments with
Metrnβ-null mice and Pparα-null mice. All experiments were
performed in accordance with European Community Council
Directive 86/609/EEC and were approved by the institutional
animal care and use committee of the University of Barcelona.
Interventions in mice and echocardiography
To induce cardiac hypertrophy, 2-mo-old male age-matched WT
and Metrnβ-null mice were anesthetized with 1.5% isoflurane,
and Alzet osmotic minipumps containing PBS or ISO (the latter
calibrated to release the drug at a rate of 15 mg/kg/d for 7 d)
were surgically implanted subcutaneously in the interscapular
region of each mouse.
To induce cardiac hypertrophy in neonates, 6-d-old WT and
PPARα-null mice were subjected to i.p. injection of ISO (15 mg/kg/
d; Sigma) for 7 d, as previously reported (Planavila et al., 2011).
To induce hypertension, 2-mo-old WT mice were anesthe-
tizedwith 1.5% isoflurane, and Alzet osmoticminipumps containing
PBS or AngII; Sigma), the latter calibrated to release AngII at a rate
of 1 mg/kg/d for 7 d, were surgically implanted subcutaneously in
the interscapular region of each mouse (Ferrer-Curriu et al., 2019).
To perform TAC to induce cardiac hypertrophy, the chest of
each mouse was opened, and the transverse aorta was ligated
between the truncus brachiocephalicus and the left common
carotid artery by tying a 6-0 silk suture against a 25-gauge
needle. Mice were sacrificed 28 d after TAC or sham operation.
In all cases, analgesia was administered for 2 d after surgery
(paracetamol 200 mg/kg/d).
In all cases, hypertrophy was assessed by echocardiography
with a Vivid Q instrument (GE Healthcare) equipped with a 12-
MHz microprobe. Ventricular measurements in M-mode and
Doppler were made after 7 d of ISO treatment. Three different
cardiac cycles were measured for each assessment, and average
values were obtained. Analyses of echocardiographic images
were performed by two different observers in a blindedmanner.
AAV vectors
AAV9-null, AAV9-GFP, and AAV9-Metrnβ were generated by
the Center for Animal Biotechnology and Gene Therapy (Bar-
celona, Spain) using a dual-triple plasmid cotransfection pro-
cedure followed by polyethylene glycol precipitation and
purification through CsCl2 gradient centrifugations. Mice were
i.p. injected at 7 d of age with AAV9-null, AAV9-GFP, and AAV9-
Metrnβ at a dose of 1013 viral genome particles per animal, as
previously described (Raso et al., 2019).
Blood pressure and heart rate
Mouse blood pressure was measured using the tail-cuff method
(BP2000; Visitech Systems). Mice were trained according to the
manufacturer’s instructions for 5 d before minipump implan-
tation. 10 consecutive measurements were averaged to calculate
the systolic, diastolic, and mean arterial blood pressures and
heart rate during the 7-d period of minipump use.
Cell culture
Rat NCMs were obtained as previously described (Planavila
et al., 2011). Briefly, hearts were digested with a collagenase
solution (Collagenase Type I; Life Technologies, Ltd.) followed by
differential plating. NCMs were stimulated with the α1-adre-
nergic agonist PE (10 μmol/liter; Sigma), which is a hypertro-
phic growth factor, and/or the proinflammatory agents LPS
(50 ng/ml; Sigma) or TNFα (50 ng/ml; Sigma). After treatment
for 24–48 h, cells were harvested for RNA isolation. Where in-
dicated, cells were treated with the PPARα antagonist GW6471
(1 μmol/liter; Sigma) or Metrnβ (OriGene Technologies, Inc.) for
24 h before being exposed to PE for an additional 24 h. Anti-
bodies against IgG (Sigma) orMetrnβ (Santa Cruz Biotechnology,
Inc.) were diluted 1:1,000 and added after the 24-h pretreatment
period.
Rat neonatal CFs were isolated from the ventricles of 1–2-d-
old Sprague-Dawley rats as described by Ferrer-Curriu et al.
(2019). P1 and P3 cells were plated at a density of 0.3 × 105 cells/
cm2 on culture dishes and grown for 24 h. Thereafter, the cells
were serum starved for 24 h and then incubated with Metrnβ
(50 nM) for another 24 h.
Adenoviral-mediated gene transduction
Recombinant adenoviruses expressing the murine Metrnβ
cDNA and the murine PPARα cDNA were constructed as pre-
viously described (Ad5-CMV-Metrnβ and Ad5-CMV-PPARα,
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respectively; Center for Animal Biotechnology and Gene Ther-
apy; Amat et al., 2009). NCMs were infected with Metrnβ or
PPARα Ads and the AdCMV-null control vector at 10 infectious
units (IFUs)/cell for 24 h in serum-free medium.
Heart histology and immunohistochemistry in mice
Each heart was extracted and cut transversely at midheight. One
half was fixed in 4% formaldehyde, embedded in paraffin, and
sectioned. The sections were deparaffinized and stained with
H&E for determination of cardiomyocyte size using ImageJ
software. Fibrosis was determined by Masson’s trichrome
staining (Panreac). Formaldehyde-fixed, paraffin-embedded
heart sections were incubated with a primary antibody against
F4/80 (Abcam). Alexa Fluor 488–conjugated goat anti-rat IgG
was used as the secondary antibody. Fluorescent micrographs
were acquired under a fluorescent microscope (Olympus BX61).
RNA isolation and real-time RT-PCR
Total RNA was extracted using Tripure (Roche). RT was per-
formed using a high-capacity RNA-to-cDNA kit (Applied Bio-
systems) and 0.5 µg RNA in a total reaction volume of 20 µl. PCR
was conducted in duplicate for increased accuracy. TaqMan
gene expression assays (Thermo Fisher Scientific) were used;
each 25-µl reaction mixture contained 1 µl cDNA, 12.5 µl Taq-
Man Universal PCR Master Mix (Thermo Fisher Scientific), 250
nM probes, and 900 nM primers from the Assays-on-Demand
Gene Expression Assay Mix or the Assays-by-Design Gene Ex-
pression AssayMix (Thermo Fisher Scientific). Each sample was
run in duplicate, and the mean value was used to calculate the
mRNA expression of the gene of interest and the housekeeping
reference gene (cyclophilin A, PPIA). The mRNA level of the
gene of interest in each sample was normalized to that of the
reference control using the comparative 2−ΔCT method.
Analysis of plasma metabolites and protein phosphorylation
Glucose and triglyceride levels were measured using the Accu-
trend Technology system (Roche Diagnostics). Metrnβ protein
levels in plasma and in NCM culture media were detected using
anMetrnβ ELISA kit (R&D Systems). Protein phosphorylation in
NCMs was assessed using the Milliplex MAP 9-plex Multi-
Pathway Signaling Magnetic Bead kit (Merck-Millipore) for
phosphorylated and total proteins.
Western blotting
Western blot analyses were performed using antibodies against
α-SMA (Sigma), PGC1α (Santa Cruz Biotechnology), phospho-
p38, p38, phospho-CREB, CREB (all from Cell Signaling Tech-
nology), and GAPDH (Sigma). Whole-cell lysates were obtained
as previously described (Planavila et al., 2005a), and proteins
were separated by 10% SDS-PAGE and transferred to Immobilon-P
membranes (Millipore).
Cardiac human biopsies for gene expression analysis
Human hearts were obtained from patients with dilated cardi-
omyopathy and final-stage HF who underwent cardiac trans-
plant (five patients). Controls were obtained from heart samples
from organ donors without a clinical history of HF and whose
heart could not be used for any reason (six controls; Planavila
et al., 2015). Written informed consent was obtained from all
participants in the human population study, which conformed to
the principles outlined in the Declaration of Helsinki. The study
was approved by the institutional ethical committee of the
Hospital Clinic of Barcelona (Barcelona, Spain) following stan-
dard procedures.
Cardiac human biopsies for histology
Hearts from donors under 70 yr of age with brain death of
cerebrovascular or traumatic origin were routinely evaluated
for possible transplantation at the transplant unit of the Hospital
Clinic (Ferrer-Curriu et al., 2019). From these samples, 6 control
hearts were collected from healthy normotensive individuals
(controls), and 21 hearts were obtained from donors with long-
standing hypertension (cases) who were not eligible for trans-
plantation because of lack of a matched recipient or inadequate
size. Of these 21 hearts, 10 exhibited clinical and echosono-
graphical criteria for dilated cardiomyopathy. We also collected
three hearts with idiopathic cardiomyopathy and five hearts
with valvular cardiomyopathy. The study protocol was approved
by the ethics committee of the Hospital Clinic (Barcelona, Spain;
reference HCB/2015/0233), and informed consent regarding the
use of myocardial tissue for this research was obtained from the
families of donors before the study. The authors of this article
certify compliance with the statement on ethics outlined in the
Declaration of Helsinki of 1975, as revised in 1983.
Human histological studies
Myocardial expression of Metrnβ was measured by im-
munostaining with an anti-Metrnβ antibody (Abcam). 6 areas of
each sample were evaluated, and a total of 200–600 cells were
assessed per field (≥1,200 cells/sample). The Metrnβ expression
index was calculated as the ratio of positively stained to nega-
tively stained myocytes. Immunohistochemical evaluations
were performed by two independent evaluators.
Human plasma samples
From May 2009 to April 2014, ambulatory patients treated at a
multidisciplinary HF clinic were consecutively included in the
study. The referral inclusion criteria and blood sample collection
were described elsewhere (Lupón et al., 2013; Bayés-Genı́s et al.,
2015; Bayes-Genis et al., 2012). All analyses of biomarkers were
performed on the same blood sample, which had been stored
at −80°C without any prior freeze–thaw cycle. All samples were
obtained between 9:00 a.m. and 12:00 p.m. All participants
provided written informed consent, and the ethics committee of
Hospital Germans Trias i Pujol (Badalona, Spain) approved the
study. All study procedures were performed in accordance with
the ethical standards outlined in the Helsinki Declaration of
1975, revised in 1983.
The primary endpoint was all-cause death. Cardiovascular
death was also assessed. A death was considered to be cardio-
vascular in origin when it was caused by HF (decompensated HF
or treatment-resistant HF, in the absence of another cause),
sudden death (unexpected death, witnessed or not, of a previ-
ously stable patient with no evidence of worsening HF or any
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other cause of death), acute myocardial infarction (due to me-
chanical, hemodynamic, or arrhythmic complications), stroke
(in association with recent acute neurological deficits), a pro-
cedural death (after diagnostic or therapeutic cardiovascular
procedures), and other cardiovascular causes (e.g., rupture of an
aneurysm, peripheral ischemia, or aortic dissection). For dis-
criminant analyses, Harrell’s C-statistic, which takes into ac-
count time to the event, unlike the usually used area under the
curve, was obtained. Computations were done following the
Fine and Gray method from R essentials for SPSS, using the
R package cmprsk, which was built by Bob Gray using R
version 3.2.5.
Statistics
Cell culture experiments were conducted on at least two inde-
pendent cardiomyocyte isolations. We used five or six mice/
group in the in vivo experiments. Results are presented as mean
± SEM. Data were analyzed by t test, one- and two-way ANOVA,
orMann-Whitney test, followed by post hoc tests as appropriate,
using GraphPad Prism software (GraphPad Software Inc.). A P
value <0.05 was considered statistically significant.
Online supplemental material
Fig. S1 shows the results of Metrnβ expression levels in human
samples and the experiments to assess AAV9 infection in mice.
Fig. S2 shows the results of antiapoptotic genes in mice and the
effects of proinflammatory stimuli in cardiomyocytes. Table S1
shows morphometric and metabolic profiles of mice. Table S2
shows blood pressure results in mice. Table S3 shows baseline
demographic and clinical characteristics of the HF patient
cohort.
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Figure S1. Metrnβ overexpression in the myocardium. (a)MetrnβmRNA expression levels in human samples from heart (n = 5), adipose tissue (n = 7), liver
(n = 8), and skeletal muscle (n = 7; Student’s t test; P values are 0.0226, 0.0096, 0.0261 versus heart). (b) Anti-GFP immunohistochemistry to assess tropism of
AAV9-GFP viruses to the myocardium. Scale bar, 2 mm. (c) Expression levels of Metrnβ in several tissues ofWT andMetrnβ−/−mice injected with AAV9-Metrnβ
or AAV9-null; n = 5 mice/group (Student’s t test; P = 0.0033 versus WT mice). (d) Circulating Metrnβ levels of WT and Metrnβ−/− mice injected with AAV9-
Metrnβ (blue bars) or AAV9-null (white bars); n = 5 mice/group (Student’s t test; P = 0.0283 versusWTmice). (e) Phosphorylation levels of different proteins in
NCMs treated with Metrnβ (0.5 µg/ml) during different times. Cell culture experiments were conducted on three independent cardiomyocyte isolations.
Results are expressed as mean ± SEM. *, P < 0.05 compared with heart (a) and with corresponding WT mice (c and d).
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Three tables are available online. Table S1 displays the morphometric and metabolic profiles of WT and Metrnβ−/− mice. Table S2
provides the blood pressure in WT and Metrnβ−/− mice and Metrnβ−/− mice injected with AAV9-Metrnβ or AAV9-null. Table S3 lists
the baseline demographic and clinical characteristics of a cohort of 446 patients with HF.
Figure S2. Role of Metrnβ in apoptotic and pro-inflammatory pathways. (a) 2-mo-old WT littermates (gray bars) and Metrnβ−/− (white bars) mice were
continuously infused with ISO for 7 d to experimentally induce heart hypertrophy. mRNA expression levels of antiapoptotic genes Bcl2, Bcl-xl, and Xiap in the
myocardium. n = 6 mice/group. Data were analyzed by two-way ANOVA (****, P < 0.00001 compared with corresponding control [CT] mice). (b) mRNA
expression levels of the hypertrophy markers Nppa and Acta1 in NCMs after PE-induced hypertrophy alone or with TNFα or LPS in NCMs overexpressing
Metrnβ (Ad-Metrnβ; blue bars) or Ad-null control vector (10 IFU/cell; gray bars). Cell culture experiments were conducted on three independent cardiomyocyte
isolations. Data were analyzed by Student’s t test. Results are expressed as mean ± SEM (P values are 0.0015, 0.02, 0.001, 0.0036, 0.003, 0.011, 0.0028,
0.0492, 0.0096, 0.0015, 0.02, 0.001, 0.0035, 0.0114, 0.0028, 0.0196; *, P < 0.05 compared with control cells; $, P < 0.05 compared with PE-treated cells).
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